Milhem Talks Mechanism of Action, Delivery Methodology, and Ongoing Trials With RP1


Dr Milhem discusses the unique mechanism of action and delivery method of RP1, which is being evaluated in the IGNYTE trial for patients with solid tumors, as well as the parallel studies ARTACUS and CERPASS, which are further exploring the agent.

Welcome to OncLiveOn Air®! I’m your host today, Jessica Hergert.

OncLiveOn Air® is a podcast from OncLive®, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive® covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions.

In today’s episode, sponsored by Replimune, we had the pleasure of speaking with Mohammed Milhem, MBBS, the Holden Chair of Experimental Therapeutics, associate director of clinical research and director of the Melanoma Program, Holden Comprehensive Cancer Center, director of the Division of Hematology, Oncology, and Blood & Marrow Transplantation, and a clinical professor at the University of Iowa Hospitals & Clinics, to discuss the unique elements of oncolytic vaccines in oncology and ongoing research with vusolimogeneoderparepvec (RP1) in melanoma and other solid tumors.

Oncolytic vaccines, such as RP1 have generated significant excitement throughout oncology, explained Milhem, citing the ease of administration, mild toxicity profile, and fast-onset responses as distinguishing features of this class of agents for patients who develop progressive disease on standard frontline therapy with PD-1 inhibitors.

In our exclusive interview, Milhem discussed the unique mechanism of action and delivery method of RP1, which is being evaluated in the IGNYTE trial (NCT03767348) for patients with solid tumors, as well as the parallel studies ARTACUS (NCT04349436) and CERPASS (NCT04050436), which are further exploring the agent.

Check back on Thursdays for exclusive interviews with leading experts in the oncology field. For more updates in oncology, be sure to visit and sign up for our e-newsletters.

OncLive is also on social media. On Twitter, follow us at @OncLive and @OncLiveSOSS. On Facebook, like us at OncLive and OncLive State of the Science Summit and follow our OncLive page on LinkedIn.

If you liked today’s episode of OncLiveOn Air®, please consider subscribing to our podcast on Apple Podcasts, Spotify, Google Podcasts, Amazon Music, and many of your other favorite podcast platforms,* so you get a notification every time a new episode is posted. While you are there, please take a moment to rate us!

Thanks again for listening to OncLiveOn Air®.

*OncLiveOn Air® is available on: Apple Podcasts, Google Podcasts, Spotify, Amazon Music, Audacy, CastBox, Deezer, iHeart, JioSaavn, Listen Notes, Player FM, Podcast Addict, Podchaser, RadioPublic, and TuneIn.

Related Videos
John M. Kirkwood, MD, Distinguished Service Professor of Medicine, Sandra and Thomas Usher Professor of Medicine, Dermatology & Translational Science, coleader, Melanoma and Skin Cancer Program, Division of Hematology/Oncology, the University of Pittsburgh
Daniel Olson, MD
Omid Hamid, MD
Michael R. Migden, MD
Daniel Olson, MD
Neil D. Gross, MD, FACS
Neil D. Gross, MD, FACS
Harriet Kluger, MD, Harvey and Kate Cushing Professor of Medicine (Oncology) and of Dermatology; director, Yale SPORE in Skin Cancer; vice chair, Translational Research, Internal Medicine; chief, Division of Skin and Kidney Cancer; associate cancer center director, Education, Training and Faculty Development; deputy section chief, Medical Oncology, Yale Cancer Center